RegulatoryCompany release

FDA extends review of Agios' mitapivat sickle cell filing to February 2027

🇺🇸 Agios Pharmaceuticals, Inc. (AGIO) · Thu 05 Nov 2026

The agency has pushed back its decision by three months after treating Agios' reply on a possible REMS as a major amendment, as the firm reported Q3 results and R&D cuts.

The US Food and Drug Administration has extended the PDUFA goal date for Agios Pharmaceuticals' supplemental new drug application for mitapivat in sickle cell disease by three months, to 1 February 2027. Agios disclosed the delay on 5 November 2026 alongside its third-quarter results.

According to the company, the extension follows the FDA's classification of Agios' response to an agency request as a major amendment. The request concerned whether a risk evaluation and mitigation strategy (REMS) is needed for the product in this indication. The summary on file does not state whether the agency has concluded that a REMS is required.

For context, a major amendment submitted during review can lead the FDA to extend a PDUFA goal date, typically by three months, to allow time to assess the new information.

On the commercial side, Agios reported net revenue of $55.4 million for mitapivat, marketed as PYRUKYND and AQVESME, in the third quarter. It attributed the figure mainly to the US launch of AQVESME in thalassemia.

The company reported $907.0 million in cash and a net loss of $65.0 million for the quarter. It also said it is reducing research and development headcount by more than 100 roles.

What it means for your team

  • Regulatory teams should note that a REMS question can become a gating item late in review and may trigger a major amendment and a longer timeline.
  • Market-access planners for sickle cell disease should shift launch assumptions for mitapivat to after the new 1 February 2027 goal date.
  • Pharmacovigilance and risk-management groups should watch for any REMS requirement, which would affect post-approval monitoring and distribution obligations.
  • The thalassemia launch figures give an early indication of uptake for the AQVESME brand in the US.

Company's press release (SEC filing): Agios Pharmaceuticals, Inc. ↗

Article written by VigiEye from the official source (Agios Pharmaceuticals, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →